Royalty Pharma, a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, completed the acquisition of Ionis Pharmaceuticals, a company in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology, for $1.125bn. “We are thrilled to partner with Ionis, an innovator in genetic medicine. This investment is consistent with our strategy of acquiring royalties on innovative therapies in areas of high unmet patient need. SPINRAZA has transformed the lives of thousands of SMA patients. We are also excited to acquire a royalty on pelacarsen which, if approved, has the potential to be a practice-changing, first-in-class therapy benefiting millions of cardiovascular disease patients by lowering Lp(a),” Pablo Legorreta, Royalty Pharma Founder and CEO.